object
report
analyz
valu
cmv
viral
load
vl
bronchoalveolar
lavag
bal
recipi
allogen
hematopoiet
stem
cell
transplant
ahsct
analyz
concord
cmv
quantif
plasma
bal
sampl
fiftysix
patient
includ
patient
symptom
lung
diseas
bal
sampl
collect
patient
vl
copiesml
six
probabl
cmv
pneumonia
patient
cmv
pneumonia
femal
median
age
year
median
time
transplant
onset
symptom
day
pneumonia
earli
three
case
incid
median
bal
vl
copiesml
plasma
vl
copiesml
one
patient
plasma
vl
neg
three
patient
improv
first
week
treatment
plasma
vl
becam
neg
patient
die
cmv
pneumonia
refractori
treatment
therefor
valu
cmv
vl
bal
especi
greater
plasma
compat
sign
symptom
consid
suggest
cmv
pneumonia
recipi
ahsct
receiv
specif
treatment
cmv
caus
sever
pneumonia
allogen
hematopoiet
stem
cell
transplant
ahsct
high
mortal
rate
spite
prevent
strategi
diagnosi
pneumonia
tradit
includ
detect
bronchoalveolar
lavag
bal
lung
tissu
sampl
viru
isol
histopatholog
test
immunohistochem
analysi
situ
hybrid
viral
isol
poor
clinic
util
low
sensit
reproduc
slow
quantif
viral
load
vl
bal
specimen
realtim
pcr
diagnos
cmv
pneumonia
evalu
suffici
determin
valu
cmv
vl
bal
patient
receiv
ahsct
pneumonia
perform
studi
patient
posit
vl
bal
follow
least
day
ahsct
januari
decemb
patient
receiv
ahsct
hospit
patient
includ
studi
exclud
die
day
caus
unrel
cmv
infect
patient
symptom
lung
diseas
bal
specimen
collect
bronchoscopi
follow
test
done
cultur
bacteria
fungi
mycobacteria
virus
pcr
assay
respiratori
syncyti
viru
influenza
b
metapneumoviru
parainfluenza
rhinoviru
adenoviru
coronaviru
pneumovir
genomica
madrid
spain
detect
pneumocysti
jirovecii
antigen
indirect
immunofluoresc
monofluo
kit
p
jirovecii
bio
rad
marneslacoquett
franc
quantif
cmv
dna
bal
plasma
sampl
obtain
simultan
perform
use
coba
ampliprepcoba
taqman
cmv
system
roch
mannheim
germani
accord
manufactur
specif
review
medic
record
patient
vl
cmv
bal
posit
describ
patient
characterist
use
percentag
median
rang
studi
approv
ethic
committe
hospit
definit
cmv
pneumonia
classifi
proven
probabl
defin
ljungman
et
al
earli
late
pneumonia
pneumonia
day
transplant
respect
refractori
infect
treatment
persist
viraemia
week
specif
antivir
treatment
cmvattribut
mortal
death
within
month
onset
symptom
cmv
diseas
caus
directli
contribut
death
patient
includ
male
median
age
year
rang
median
followup
time
day
rang
thirtyf
patient
plasma
cmv
reactiv
first
day
transplant
patient
bal
sampl
collect
vl
cmv
bal
posit
patient
copiesml
copiesml
neg
patient
neg
virolog
cultur
sampl
insuffici
vl
three
patient
vl
less
copiesml
diagnos
idiopath
pneumonia
good
evolut
ganciclovir
treatment
patient
bal
vl
higher
copiesml
diagnos
probabl
cmv
pneumonia
case
cmv
diseas
discount
patient
present
day
posttranspl
respiratori
symptom
bilater
interstiti
infiltr
pleural
effus
vl
undetect
plasma
bal
specimen
day
post
transplant
plasma
viremia
copiesml
detect
ganciclovir
treatment
start
day
patient
clinic
improv
radiolog
improv
plasma
vl
copiesml
bal
vl
copiesml
plasma
bal
vl
becam
undetect
without
complet
clinic
radiolog
improv
die
day
post
transplant
alveolar
hemorrhag
associ
bronchiol
obliteran
context
chronic
gvhd
tumor
progress
tabl
show
clinic
epidemiolog
microbiolog
characterist
six
patient
cmv
pneumonia
patient
patient
femal
median
age
year
old
rang
median
time
transplant
onset
symptom
rang
day
pneumonia
present
earli
three
case
incid
late
three
median
bal
vl
log
copiesml
rang
five
case
plasma
vl
posit
median
log
copiesml
rang
patient
plasma
vl
less
bal
vl
one
case
plasma
vl
neg
one
bal
sampl
posit
cmv
virolog
cultur
vl
copiesml
none
case
anoth
pathogen
detect
patient
treat
valganciclovir
ganciclovir
three
ad
chang
foscarnet
two
patient
clinic
deterior
detect
plasma
vl
day
initi
therapi
case
one
advers
event
case
one
patient
receiv
earli
therapi
case
three
patient
clinic
radiolog
improv
first
day
follow
start
treatment
reduct
plasma
vl
undetect
three
patient
die
diagnosi
cmv
pneumonia
refractori
treatment
day
start
treatment
ahstc
patient
cmv
pneumonia
ahsct
remain
common
complic
high
mortal
even
specif
treatment
diagnost
test
high
sensit
speed
bal
vl
use
identifi
patient
earli
stage
infect
patient
risk
develop
pneumonia
valid
diagnosi
diseas
far
know
first
studi
evalu
role
vl
bal
diagnosi
pneumonia
regard
clinic
data
patient
receiv
ahsct
analyz
concord
cmv
quantit
plasma
bal
specimen
studi
analyz
valu
vl
bal
patient
popul
mainli
lungtranspl
patient
consid
high
vl
copiesml
copiesml
suggest
cmv
pneumonia
studi
patient
probabl
cmv
pneumonia
wide
rang
copiesml
vl
median
copiesml
howev
patient
bal
vl
less
copiesml
includ
three
patient
load
copiesml
respond
treatment
ganciclovir
good
cmv
viral
load
bal
ahsct
l
iglesia
et
al
evolut
could
relat
earli
stage
diseas
moreov
patient
vl
higher
copiesml
die
refractori
pneumonia
nonrespons
treatment
patient
high
vl
could
relat
advanc
clinic
stage
resist
ganciclovir
patient
plasma
vl
lower
bal
one
patient
even
undetect
plasma
vl
fact
describ
author
could
impli
plasma
vl
monitor
limit
anticip
develop
pneumonia
therefor
low
undetect
viremia
level
exclud
cmv
pneumonia
patient
detect
bal
vl
without
cmv
pneumonia
bal
vl
higher
plasma
studi
patient
receiv
ahsct
diagnos
probabl
cmv
pneumonia
high
percentag
mortal
specif
treatment
describ
studi
factor
associ
increas
mortal
persist
cmv
dnaemia
week
spite
antivir
therapi
could
relat
ganciclovir
resist
although
could
analyz
fact
two
patient
die
treatment
chang
foscarnet
late
day
ganciclovir
treatment
plasma
vl
becom
neg
studi
virolog
cultur
perform
low
sampl
bal
vl
million
copiesml
posit
could
patient
alreadi
begun
antivir
treatment
sampl
taken
lower
perform
cell
cultur
vl
low
conclus
base
result
valu
cmv
vl
bal
especi
greater
plasma
could
consid
suggest
cmv
pneumonia
patient
receiv
ahsct
patient
receiv
specif
treatment
without
specif
treatment
mortal
could
high
howev
studi
assess
bal
vl
patient
reciev
ahsct
necessari
believ
studi
spite
low
number
patient
import
public
bal
cmv
vl
evalu
patient
ahsct
note
convent
diagnosi
method
bal
plasma
vl
limit
low
perform
test
quantifi
vl
cmv
avail
mani
clinic
microbiolog
laboratori
advantag
could
use
quantifi
bal
vl
sampl
result
extrapol
popul
hiv
solid
organ
transplant
recipi
